Clinical Trials Logo

Maximum Tolerated Dose clinical trials

View clinical trials related to Maximum Tolerated Dose.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04138381 Active, not recruiting - Drug Use Clinical Trials

Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)

SeliGIST
Start date: August 16, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, two cohort, open label phase I/II clinical trial studying the combination of oral imatinib 400 mg, once daily, and oral selinexor given once weekly (Cohort A); and single-agent oral selinexor 60 mg BIW (Cohort B). The study will consist of: - Cohort A: an initial escalation phase (Ib) evaluating increasing doses of selinexor in combination with fixed doses of imatinib administered in repeated 28-day cycles in advanced/metastatic, imatinib-resistant GIST patients, followed by an expansion phase (II) testing for safety and preliminary evidence of antitumor activity - Cohort B: single-agent, fixed selinexor dose in the same target population